Currently out of the existing stock ratings of Konstantinos Aprilakis, 20 are a BUY (83.33%), 3 are a HOLD (12.5%), 1 are a SELL (4.17%).

Konstantinos Aprilakis

Work Performance Price Targets & Ratings Chart

Analyst Konstantinos Aprilakis, carries an average stock price target met ratio of 46.43% that have a potential upside of 82.53% achieved within 326 days. Previously, Konstantinos Aprilakis worked at STIFEL, DEUTSCHE BANK.

Konstantinos Aprilakis’s has documented 47 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on STRO, Sutro Biopharma at 21-Jan-2021.

Wall Street Analyst Konstantinos Aprilakis

Analyst best performing recommendations are on STRO (SUTRO BIOPHARMA).
The best stock recommendation documented was for STRO (SUTRO BIOPHARMA) at 12/2/2020. The price target of $25 was fulfilled within 37 days with a profit of $8.65 (52.91%) receiving and performance score of 14.3.

Average potential price target upside

of $11.49 (61.26%) on KURA (KURA ONCOLOGY).
of $10.44 (12.15%) on BPMC (BLUEPRINT MEDICINES CORP).
of $9.74 (74.94%) on STRO (SUTRO BIOPHARMA).

BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC KURA Kura Oncology SNDX Syndax Pharmaceuticals STRO Sutro Biopharma MOR MorphoSys AG ADR ANAB AnaptysBio SGEN Seagen

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Derek Archila (WELLS FARGO)